阿尔茨海默病中认知储备与临床进展的矛盾关系
研究纳入839名β-淀粉样蛋白阳性的ADNI参与者,用灰质体积或白质高信号体积的标准化残差量化认知储备。校正年龄、性别、APOE4状态和基线脑损伤后,较高的灰质体积认知储备与痴呆前阶段诊断转换风险降低及记忆和执行功能下降减慢相关,但在AD痴呆阶段则与更快的认知下降相关。
要点
- Aβ阳性人群中,较高认知储备在痴呆前阶段延缓临床进展。
- AD痴呆阶段较高认知储备反而加速认知下降。
- 认知储备的临床效应随疾病阶段不同而方向相反。
核心结论
- 在Aβ阳性个体中,较高认知储备在AD痴呆前阶段减缓临床进展,但在痴呆 onset 后加速认知下降。
研究设计与样本
- 从ADNI选取839名β-淀粉样蛋白阳性参与者,包括认知正常175人、轻度认知障碍437人、AD痴呆227人。
- 认知储备用协变量校正线性回归的标准化残差(W分数)量化,自变量为全局认知(13项ADAS-cog),因变量为灰质体积或白质高信号体积。
- 中位随访24个月(四分位距6-42个月)。
主要发现
- 校正年龄、性别、APOE4状态和基线脑损伤后,较高灰质体积W分数与较低诊断转换风险相关(HR 0.22,p < 0.001)。
- 较高灰质体积W分数与记忆下降减慢(β = 0.48,p < 0.001)和执行功能下降减慢(β = 0.67,p < 0.001)相关。
- 认知正常亚组:诊断转换HR 0.30(p = 0.038),ADNI-MEM β = 0.52(p = 0.028),ADNI-EF β = 0.42(p = 0.077)。
- 轻度认知障碍亚组:诊断转换HR 0.21(p < 0.001),ADNI-MEM β = 0.43(p = 0.003),ADNI-EF β = 0.59(p < 0.001)。
- AD痴呆亚组:ADNI-MEM β = -0.91(p = 0.002),ADNI-EF β = -0.77(p = 0.081),提示更快速下降。
临床怎么用
- 对Aβ阳性的痴呆前阶段患者,较高认知储备提示临床进展可能较慢。
- 对已进入AD痴呆阶段的患者,较高认知储备可能预示更快的认知下降,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the relationship between cognitive reserve (CR) and clinical progression across the Alzheimer disease (AD) spectrum. METHODS: We selected 839 β-amyloid (Aβ)-positive participants with normal cognition (NC, n = 175), mild cognitive impairment (MCI, n = 437), or AD dementia (n = 227) from the Alzheimer's Disease Neuroimaging Initiative (ADNI). CR was quantified using standardized residuals (W scores) from a (covariate-adjusted) linear regression with global cognition (13-item Alzheimer's Disease Assessment Scale-cognitive subscale) as an independent variable of interest, and either gray matter volumes or white matter hyperintensity volume as dependent variables. These W scores, reflecting whether an individual's degree of cerebral damage is lower or higher than clinically expected, were tested as predictors of diagnostic conversion (i.e., NC to MCI/AD dementia, or MCI to AD dementia) and longitudinal changes in memory (ADNI-MEM) and executive functions (ADNI-EF). RESULTS: The median follow-up period was 24 months (interquartile range 6-42). Corrected for age, sex, APOE4 status, and baseline cerebral damage, higher gray matter volume-based W scores (i.e., greater CR) were associated with a lower diagnostic conversion risk (hazard ratio [HR] 0.22, p < 0.001) and slower decline in memory (β = 0.48, p < 0.001) and executive function (β = 0.67, p < 0.001). Stratified by disease stage, we found similar results for NC (diagnostic conversion: HR 0.30, p = 0.038; ADNI-MEM: β = 0.52, p = 0.028; ADNI-EF: β = 0.42, p = 0.077) and MCI (diagnostic conversion: HR 0.21, p < 0.001; ADNI-MEM: β = 0.43, p = 0.003; ADNI-EF: β = 0.59, p < 0.001), but opposite findings (i.e., more rapid decline) for AD dementia (ADNI-MEM: β = -0.91, p = 0.002; ADNI-EF: β = -0.77, p = 0.081). CONCLUSIONS: Among Aβ-positive individuals, greater CR related to attenuated clinical progression in predementia stages of AD, but accelerated cognitive decline after the onset of dementia.
引用
- van Loenhoud AC, van der Flier WM, Wink AM, et al. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship. Neurology. 2019. PMID: 31266904. doi:10.1212/WNL.0000000000007821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。